March 1, 2019, MedPage Today 

The identification of biomarkers to cluster breast cancer patients into subgroups based on their immune evasion mechanisms may help guide the choice of immunotherapy, according to new research. The findings provide a better understanding of the response to immunotherapies and shed light on the rational design of novel combination therapies, the team said. 

Read more.